Join
Live feed
·
INSIDERFilingvia Quantisnow
Taysha Gene Therapies Inc. logo

President and Head of R&D Nagendran Sukumar sold $1,248,000 worth of shares (200,000 units at $6.24) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 936,410 units (SEC Form 4)

ByQuantisnow·Wall Street's wire, on your screen.
TSHA· Taysha Gene Therapies Inc.
Health Care
Original source

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TSHA (Taysha Gene Therapies Inc.) and more on Quantisnow.

President and Head of R&D Nagendran Sukumar sold $1,248,000 worth of shares (200,000 units at $6.24) as part of a pre-agreed trading plan, decreasing direct ownership by 18% to 936,410 units (SEC Form 4) | Quantisnow